SCHEMBL21516319

SCHEMBL21516319

Cc1cc(N2CCCCCC2c2cccc(F)c2)nc(N)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NTRK1 P04629 13/20 0.46
JAK2 O60674 5/20 0.46
NTRK3 Q16288 3/20 0.44
NTRK2 Q16620 3/20 0.44
INSR P06213 1/20 0.42
LYN P07948 1/20 0.42
RET P07949 1/20 0.42
MET P08581 1/20 0.42
ROS1 P08922 1/20 0.42
FGR P09769 1/20 0.42
KIT P10721 1/20 0.42
FGFR4 P22455 1/20 0.42
FGFR3 P22607 1/20 0.42
TIE1 P35590 1/20 0.42
KDR P35968 1/20 0.42
FLT3 P36888 1/20 0.42
ALK Q9UM73 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29456676 1.00 CRHBP (0.47) CRHBPCRHR2SMN1; SMN2NTRK1JAK2
SCHEMBL21516622 0.87 CRHBP (0.50) CRHBPCRHR2SMN1; SMN2JAK2LMNA
SCHEMBL29456372 0.87 CRHBP (0.50) CRHBPCRHR2SMN1; SMN2JAK2LMNA
SCHEMBL21516542 0.87 CRHBP (0.52) CRHBPCRHR2SMN1; SMN2LMNAKDM4E
SCHEMBL29456413 0.87 CRHBP (0.52) CRHBPCRHR2SMN1; SMN2LMNAKDM4E
SCHEMBL21516321 0.87 CRHBP (0.47) CRHBPCRHR2SMN1; SMN2KDM4EMAPT
SCHEMBL29456371 0.87 CRHBP (0.47) CRHBPCRHR2SMN1; SMN2KDM4EMAPT
SCHEMBL24313462 0.84 CRHBP (0.47) CRHBPCRHR2SMN1; SMN2NTRK1JAK2
SCHEMBL24313227 0.83 CRHBP (0.45) CRHBPCRHR2SMN1; SMN2NTRK1JAK2
SCHEMBL24313121 0.83 CRHBP (0.45) CRHBPCRHR2SMN1; SMN2NTRK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 US disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 US disclosed
EP-4043460-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF Merck Patent GmbH (DE) 2022-08-17 EP disclosed
EP-3784666-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2022-03-16 EP disclosed
CN-112236428-A Antiproliferative compounds and uses thereof 默克专利股份有限公司 2021-01-15 CN disclosed
US-10815225-B2 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2020-10-27 US disclosed
US-20190322658-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190322658-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885
US-10815225-B2 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.